JP2014503525A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503525A5
JP2014503525A5 JP2013543801A JP2013543801A JP2014503525A5 JP 2014503525 A5 JP2014503525 A5 JP 2014503525A5 JP 2013543801 A JP2013543801 A JP 2013543801A JP 2013543801 A JP2013543801 A JP 2013543801A JP 2014503525 A5 JP2014503525 A5 JP 2014503525A5
Authority
JP
Japan
Prior art keywords
compound according
group
alkyl
motomeko
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013543801A
Other languages
English (en)
Japanese (ja)
Other versions
JP5945278B2 (ja
JP2014503525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/073011 external-priority patent/WO2012080447A1/en
Publication of JP2014503525A publication Critical patent/JP2014503525A/ja
Publication of JP2014503525A5 publication Critical patent/JP2014503525A5/ja
Application granted granted Critical
Publication of JP5945278B2 publication Critical patent/JP5945278B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013543801A 2010-12-16 2011-12-16 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール Active JP5945278B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195468 2010-12-16
EP10195468.3 2010-12-16
PCT/EP2011/073011 WO2012080447A1 (en) 2010-12-16 2011-12-16 Indoles as respiratory syncytial virus antiviral agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016048038A Division JP2016145236A (ja) 2010-12-16 2016-03-11 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール

Publications (3)

Publication Number Publication Date
JP2014503525A JP2014503525A (ja) 2014-02-13
JP2014503525A5 true JP2014503525A5 (cg-RX-API-DMAC7.html) 2014-07-10
JP5945278B2 JP5945278B2 (ja) 2016-07-05

Family

ID=43875270

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013543801A Active JP5945278B2 (ja) 2010-12-16 2011-12-16 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール
JP2016048038A Pending JP2016145236A (ja) 2010-12-16 2016-03-11 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016048038A Pending JP2016145236A (ja) 2010-12-16 2016-03-11 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール

Country Status (31)

Country Link
US (3) US8921560B2 (cg-RX-API-DMAC7.html)
EP (1) EP2651922B1 (cg-RX-API-DMAC7.html)
JP (2) JP5945278B2 (cg-RX-API-DMAC7.html)
KR (1) KR101914606B1 (cg-RX-API-DMAC7.html)
CN (1) CN103347875B (cg-RX-API-DMAC7.html)
AR (1) AR084335A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011343256C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013011949B1 (cg-RX-API-DMAC7.html)
CA (1) CA2822000C (cg-RX-API-DMAC7.html)
CL (1) CL2013001715A1 (cg-RX-API-DMAC7.html)
CY (1) CY1117763T1 (cg-RX-API-DMAC7.html)
DK (1) DK2651922T3 (cg-RX-API-DMAC7.html)
EA (1) EA022339B1 (cg-RX-API-DMAC7.html)
ES (1) ES2572258T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160533T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028009T2 (cg-RX-API-DMAC7.html)
IL (1) IL225641A (cg-RX-API-DMAC7.html)
ME (1) ME02406B (cg-RX-API-DMAC7.html)
MX (1) MX339944B (cg-RX-API-DMAC7.html)
MY (1) MY163981A (cg-RX-API-DMAC7.html)
NZ (1) NZ609487A (cg-RX-API-DMAC7.html)
PH (1) PH12013500797A1 (cg-RX-API-DMAC7.html)
PL (1) PL2651922T3 (cg-RX-API-DMAC7.html)
RS (1) RS54746B1 (cg-RX-API-DMAC7.html)
SG (1) SG189866A1 (cg-RX-API-DMAC7.html)
SI (1) SI2651922T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600142B (cg-RX-API-DMAC7.html)
TW (1) TWI515187B (cg-RX-API-DMAC7.html)
UA (1) UA109792C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012080447A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201304423B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
KR102092612B1 (ko) 2012-06-15 2020-03-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 호흡기 합포체 바이러스의 항바이러스제로서의 헤테로사이클로 치환된 1,3-디하이드로-2h-벤즈이미다졸-2-온 유도체
AU2013276521A1 (en) * 2012-06-15 2014-12-04 Janssen Sciences Ireland Uc 1,3 -dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
WO2014009302A1 (en) * 2012-07-10 2014-01-16 F. Hoffmann-La Roche Ag Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection
EP2909195B1 (en) 2012-10-16 2017-06-14 Janssen Sciences Ireland UC Rsv antiviral compounds
HK1225716A1 (zh) 2013-08-21 2017-09-15 Alios Biopharma, Inc. 抗病毒化合物
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為rsv抗病毒化合物之螺脲化合物
CA2957017A1 (en) * 2014-08-05 2016-02-11 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
EA201792028A1 (ru) 2015-03-13 2018-04-30 Форма Терапьютикс, Инк. Альфа-цинамидные соединения и композиции как ингибиторы hdac8
MX381798B (es) 2015-07-22 2025-03-13 Enanta Pharm Inc Derivados de benzodiazepina como inhibidores de rsv
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
MY197217A (en) 2016-02-03 2023-06-01 Janssen Sciences Ireland Uc Combination products for the treatment of rsv
KR20180125960A (ko) 2016-03-15 2018-11-26 바이엘 크롭사이언스 악티엔게젤샤프트 동물 해충을 방제하기 위한 치환된 술포닐 아미드
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10881666B2 (en) 2017-09-29 2021-01-05 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
JP7228588B2 (ja) 2017-11-13 2023-02-24 エナンタ ファーマシューティカルズ インコーポレイテッド ベンゾジアゼピン-2-オンおよびベンゾアゼピン-2-オン誘導体の分割方法
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療rsv
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
TWI864048B (zh) 2019-10-04 2024-12-01 美商安塔製藥公司 抗病毒雜環化合物、其醫藥組成物及其用途
EP4051663B1 (en) * 2019-10-30 2024-02-21 Janssen Sciences Ireland Unlimited Company Synthesis of 3-nitro-n-(2,2,2-trifluoroethyl)-4-pyridinamine
CN114630828B (zh) 2019-10-30 2023-10-31 杨森科学爱尔兰无限公司 一种rsv抑制化合物的合成
CN114641467A (zh) 2019-11-07 2022-06-17 拜耳公司 用于防治动物有害物的取代的磺酰胺
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US12145933B2 (en) 2020-06-11 2024-11-19 Janssen Sciences Ireland Unlimited Company Hemi (L)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethy)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one and pharmaceutical compositions comprising the same
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2022182861A1 (en) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2022184606A1 (en) 2021-03-01 2022-09-09 Janssen Sciences Ireland Unlimited Company Synthesis of rilematovir
CN114014856B (zh) * 2021-11-26 2023-12-22 嘉兴安谛康生物科技有限公司 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514162A (ja) 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Xa因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
AU1099000A (en) 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
BR9916363A (pt) 1998-12-18 2001-12-11 Axys Pharm Inc Composto, composição farmacêutica e método paratratar ou prevenir um distúrbio tromboembólico
EE04591B1 (et) 1999-06-28 2006-02-15 Janssen Pharmaceutica N.V. Respiratoorse süntsütiaalviiruse replikatsiooni inhibiitorid, nende valmistamismeetod, kasutamine ja vaheühendid, farmatseutiline kompositsioon ja selle valmistamismeetod ning produkt
TR200103804T2 (tr) 1999-06-28 2002-05-21 Janssen Pharmaceutica N.V. Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler
US6534535B1 (en) * 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU2001234705A1 (en) * 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indalone and benzimidazolone inhibitors of factor xa
AU2001236605A1 (en) * 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indole and benzimidazole inhibitors of factor xa
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
PL369432A1 (en) 2001-12-10 2005-04-18 Bristol-Myers Squibb Company Bis hydrochloride monohydrate salt of rsv fusion inhibitor
US20030180957A1 (en) 2001-12-21 2003-09-25 Sense Proteomic Limited Target and method
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
AR043692A1 (es) 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
US7343930B2 (en) 2004-12-03 2008-03-18 Masco Corporation Of Indiana Sprayer with non-faucet control
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
CA2687821C (en) 2007-05-22 2015-04-14 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
TWI515187B (zh) * 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI530495B (zh) * 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI541241B (zh) * 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
JP6145044B2 (ja) 2010-12-17 2017-06-07 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 薬剤投与
AU2013276521A1 (en) 2012-06-15 2014-12-04 Janssen Sciences Ireland Uc 1,3 -dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
KR102092612B1 (ko) 2012-06-15 2020-03-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 호흡기 합포체 바이러스의 항바이러스제로서의 헤테로사이클로 치환된 1,3-디하이드로-2h-벤즈이미다졸-2-온 유도체
AU2013276518A1 (en) 2012-06-15 2014-12-04 Janssen Sciences Ireland Uc 4 - substituted 1, 3 - dihydro - 2H - benzimidazol - 2 - one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
EA201590020A1 (ru) 2012-06-15 2015-03-31 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
EP2909195B1 (en) 2012-10-16 2017-06-14 Janssen Sciences Ireland UC Rsv antiviral compounds

Similar Documents

Publication Publication Date Title
JP2014503525A5 (cg-RX-API-DMAC7.html)
JP2013545785A5 (cg-RX-API-DMAC7.html)
JP2017504635A5 (cg-RX-API-DMAC7.html)
JP2008509166A5 (cg-RX-API-DMAC7.html)
JP2015505296A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2017509586A5 (cg-RX-API-DMAC7.html)
JP2012092103A5 (cg-RX-API-DMAC7.html)
WO2012122340A8 (en) Soluble guanylate cyclase activators
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2013521295A5 (cg-RX-API-DMAC7.html)
JP2014506907A5 (cg-RX-API-DMAC7.html)
JP2016506962A5 (cg-RX-API-DMAC7.html)
JP2014051526A5 (cg-RX-API-DMAC7.html)
JP2014500265A5 (cg-RX-API-DMAC7.html)
JP2018531941A5 (cg-RX-API-DMAC7.html)
JP2011513410A5 (cg-RX-API-DMAC7.html)
JP2008540554A5 (cg-RX-API-DMAC7.html)
JP2018515563A5 (cg-RX-API-DMAC7.html)
JP2016510000A5 (ja) 治療用化合物
JP2016507575A5 (cg-RX-API-DMAC7.html)
JP2016529319A5 (cg-RX-API-DMAC7.html)
SI3102573T1 (en) SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7
JP2015517532A5 (cg-RX-API-DMAC7.html)
JP2017525699A5 (cg-RX-API-DMAC7.html)